Company intelligence / Profile preview
Syngulon
Liege, Belgiumsyngulon.com ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Preclinical
01
Overview
Syngulon's bacteriocin-based genetic technologies have shown efficacy in laboratory settings for improving microbial fermentation efficiency and preventing contamination. The company is actively collaborating with academic partners on research programs targeting both industrial and human health applications but has not reported clinical trial results yet.
- Therapeutic areas
- OtherInfectious Diseases
- Modalities
- Genetically engineered bacteriocins (antimicrobial peptides)Genetic technologies for microbial strain engineering
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
UCLouvainULBKU LeuvenImperial College LondonUniversity College LondonUniversidad Complutense MadridDSMCentrient PharmaceuticalsTereos
Beyond the preview
Go deeper on Syngulon.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Syngulon.